Methylfolate vs folic acid: which belongs in a preconception product?

If you are specifying a preconception or prenatal formulation, this decision comes up and it carries a real cost difference. Methylfolate is sold at a premium on the strength of an argument about the MTHFR gene, and that argument is partly sound and substantially oversold.

Here is the comparison as a formulator needs it, and as a buyer should understand it.

This is information, not medical advice. Folate requirements before and during pregnancy should be set by your doctor. Do not change a prescribed dose based on an article.

The short verdict

For the general preconception case, folic acid is the right choice, it is the form with the neural tube defect prevention evidence behind it, it is what public health programmes use, it is stable, and it is inexpensive.

Methylfolate is a reasonable premium option for a product aimed at a segment that asks for it, and has a genuine rationale in specific situations.

What is not defensible is positioning folic acid as ineffective or unsafe, which is how much methylfolate marketing is written.

The two forms

Folic acid is the synthetic, fully oxidised form: pteroylmonoglutamic acid. It is not the form found in food, and it is not the form the body uses directly. It must be reduced and methylated, with the final step producing 5-methyltetrahydrofolate.

Methylfolate, L-5-methyltetrahydrofolate, sold as L-5-MTHF or under trade names, is that end product, supplied directly. It is also the predominant circulating form of folate in blood.

So methylfolate skips the conversion. That is the whole mechanical argument, and it is accurate as far as it goes.

The MTHFR argument, stated fairly

The MTHFR gene encodes methylenetetrahydrofolate reductase, the enzyme performing the final conversion step. Common variants, C677T most discussed, reduce that enzyme’s activity. The homozygous TT genotype has substantially reduced activity; the heterozygous CT genotype is mildly reduced.

These variants are common. Depending on the population studied, a large fraction of people carry at least one copy.

The marketing conclusion: you probably have a variant, so folic acid does not work for you, so you need methylfolate.

Where that conclusion overreaches:

Reduced enzyme activity is not absent activity. People with MTHFR variants still convert folate; they do so somewhat less efficiently, and the body has considerable capacity in this pathway.

More decisively: the neural tube defect prevention evidence was generated with folic acid, in trials and in population-level fortification programmes, in populations that included the full normal distribution of MTHFR genotypes. Folic acid worked across those populations. It was not stratified by genotype because it did not need to be.

Major obstetric bodies and public health agencies continue to recommend folic acid for periconceptional supplementation. They are aware of MTHFR. Routine MTHFR genotyping is generally not recommended as part of fertility or preconception workup, and several professional societies have said so explicitly.

Where the premium is genuinely justified

Three situations, and a brand aiming at a premium segment can speak to them honestly.

1. People who already know their genotype. Direct-to-consumer genetic testing is growing, and someone who has seen “MTHFR C677T homozygous” on a report will seek methylfolate. The physiological rationale for them is at its strongest, and the reassurance has value even where the clinical difference is modest.

2. Unmetabolised folic acid concerns. At higher intakes, unmetabolised folic acid appears in circulation. Whether this carries any health consequence is genuinely unresolved, it is an active research question, not a settled harm. Methylfolate avoids the issue entirely, which some clinicians prefer as a precaution.

3. The informed-consumer segment. A meaningful part of the premium supplement market reads about forms and asks for the active ones. Giving them methylfolate is a legitimate product decision for that audience, regardless of whether the clinical gain is measurable.

Where folic acid genuinely wins

Evidence. This is the decisive one for a preconception product. The outcome everyone actually cares about, reduced neural tube defects, has been demonstrated with folic acid, repeatedly, at population scale. Methylfolate raises blood folate effectively; it does not have an equivalent body of outcome evidence for that endpoint.

Cost. The difference is large. In a multi-ingredient formulation at Indian price points, it can decide whether the product reaches the mass market at all.

Stability. Folic acid is notably stable. Methylfolate is more sensitive to heat, moisture and light; the stabilised salt forms used commercially address this, at further cost, and shelf-life specification needs more care.

Regulatory familiarity. Folic acid is long-established in Indian supplement and fortification practice. Methylfolate is accepted but less routine, which can mean more documentation at approval.

Supply. Folic acid is widely available from many suppliers. Methylfolate supply is narrower, with the recognised branded forms costing more and generic material of more variable quality.

Side by side

	Folic acid	Methylfolate
Chemical form	Pteroylmonoglutamic acid	L-5-methyltetrahydrofolate
Conversion needed	Yes, several steps	No
NTD prevention evidence	Extensive, population scale	Not equivalent for that endpoint
Raises blood folate	Yes	Yes
Affected by MTHFR variants	Conversion less efficient	Bypasses the step
Unmetabolised folic acid	Possible at higher intakes	Not applicable
Cost	Low	Several times higher
Stability	Very good	Needs a stabilised salt, more care
Supply breadth	Wide	Narrower
Public health recommendation	Yes	Not the standard recommendation

Where the difference does not matter

Honestly: for most people, most of the time.

Someone without an MTHFR variant, taking an adequate dose of either form, gets adequate folate. Someone heterozygous likewise. The body’s capacity in this pathway is substantial.

And a point that gets lost in the forms argument: the dose and the timing matter far more than the form. Folate’s protective effect against neural tube defects depends on adequate status in the weeks before and immediately after conception, before most people know they are pregnant.

Which means the single most important thing in this category is not which form is in the bottle. It is that anyone who might become pregnant is taking folate at all, early enough. A perfect methylfolate product started in the eighth week has missed the window that mattered.

How to decide for your formulation

Mass-market preconception or prenatal product: folic acid. Evidence, cost and stability all point the same way, and you can state the public health rationale confidently.

Premium or practitioner channel: methylfolate, or both forms. The segment asks for it, the rationale is defensible, and the price point supports it.

Covering both audiences: a combination is used commercially and lets you speak to the MTHFR-aware customer without abandoning the evidence-backed form.

What we will not put on artwork, whichever form you choose:

• That folic acid is ineffective, unusable, or unsafe
• That the product prevents birth defects, that is a medicinal claim
• That the product treats infertility or improves fertility outcomes
• MTHFR testing recommendations, which is clinical advice and not ours to give on a label

What is sayable: folate’s recognised role in normal cell division and in maternal tissue growth during pregnancy, and the form used, stated plainly.

If you are buying rather than formulating

Three things, in order of importance:

1. Start early. Before conception, not after a positive test. This matters more than everything below it.
2. Take the dose your doctor sets. Higher-risk pregnancies get higher doses, and that is a medical decision.
3. Then, if you like, choose the form. If you know you carry a variant, or you prefer to avoid unmetabolised folic acid, methylfolate is a sound choice. If not, folic acid is the form with the outcome evidence and there is nothing second-rate about it.

And do not get MTHFR tested on the strength of supplement marketing. If it is clinically indicated, your doctor will say so.

The short version

Methylfolate is the biologically active form and skips a conversion step. Folic acid is the form with the neural tube defect evidence behind it, at a fraction of the cost and with better stability.

MTHFR variants are common and real; reduced conversion is not absent conversion, and folic acid demonstrably worked in populations full of these variants. Use folic acid for the mass market, methylfolate for the segment that asks, and remember that starting early beats either form.

Composition detail: Conceivo 360.